Mikhail Blagosklonny is a renowned scientist whose deep contribution in the field of cancer and aging is unparalleled. Mikhail is an oncology professor at Roswell Park Cancer Institute. The scientist is a graduate of the renowned First Pavlov State Medical University, St, Petersburg where he pursued his PhD in experimental medicine and M.D in internal medicine. Mikhail worked as an associate professor of medicine in Valhalla at the New York Medical College before joining Roswell in 2009. His deep interest in cancer and aging has seen him conduct extensive researches on the same. In particular, his studies have focused on cancer treatment that prevents damage of the normal cell as well as the mechanism of aging and anti-aging drugs. Read more on Impact Journals.
Mikhail’s research has also zeroed in on other fields, including cell cycle, mitosis, signal transduction, apoptosis, oncogenes suppressors, and anticancer therapeutics. He is the editor-in-chief of Oncotarget journal as well as Aging and Cell Cycle. Oncotarget is an online peer-reviewed weekly journal that publishes papers that focus on oncology and beyond. Cell Cycle is a bi-weekly peer-reviewed journal that publishes scientific papers. Aging is a peer-reviewed medical journal, which is published by impact journals on a monthly basis. Mikhail Blagosklonny serves as an associate editor for Cancer Biology & Therapy. In addition, he plays an active role on the editorial board of Cell Death and Differentiation. Mikhail has also worked for PLOS ONE, The American Journal of Pathology, Autophagy and International Journal of Cancer. Blagosklonny is the author of over 200 research articles, book chapters and reviews. He is also famous for his Hyper function theory of aging as well as chemotherapeutic engineering and cell clotherapy anti-cancer approaches.
He is renowned for his hypothesis of the role of TOR signaling in cancer and aging where he proposed the use of a popular cancer drug known as Rapamycn. He also researched on molecular damage in cancer and aging where he focused on TOR initiated aging. He explained that aging is defined by molecular damage. However, on its own, molecular damage cannot cause death in organisms. He determined that TOR signaling could be inhibited to extend the life of cancer patients. Check Mikhail’s profile in LinkedIn